Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis

BACKGROUND: Treatment with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) is a well-established therapy for advanced Hodgkin’s lymphoma (HL). However, the recently completed ECHELON-1 trial showed potential net clinical benefit for brentuximab vedotin (BREN+AVD) compared to ABVD as fron...

Descripción completa

Detalles Bibliográficos
Autores principales: Raymakers, A. J. N., Costa, S., Cameron, D., Regier, D. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557030/
https://www.ncbi.nlm.nih.gov/pubmed/33050897
http://dx.doi.org/10.1186/s12885-020-07374-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557030/
https://www.ncbi.nlm.nih.gov/pubmed/33050897
http://dx.doi.org/10.1186/s12885-020-07374-3

Ejemplares similares